Free Trial
NASDAQ:BNOX

Bionomics (BNOX) Stock Price, News & Analysis

Bionomics logo
$0.29 +0.02 (+7.28%)
(As of 11/22/2024 ET)

About Bionomics Stock (NASDAQ:BNOX)

Key Stats

Today's Range
$0.27
$0.30
50-Day Range
$0.19
$0.68
52-Week Range
$0.18
$1.95
Volume
446,549 shs
Average Volume
28.79 million shs
Market Capitalization
$5.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Bionomics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

BNOX MarketRank™: 

Bionomics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bionomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bionomics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bionomics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bionomics are expected to grow in the coming year, from ($1.03) to ($0.42) per share.

  • Price to Book Value per Share Ratio

    Bionomics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.10% of the outstanding shares of Bionomics have been sold short.
  • Short Interest Ratio / Days to Cover

    Bionomics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bionomics has recently increased by 1,278.99%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bionomics does not currently pay a dividend.

  • Dividend Growth

    Bionomics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.10% of the outstanding shares of Bionomics have been sold short.
  • Short Interest Ratio / Days to Cover

    Bionomics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bionomics has recently increased by 1,278.99%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bionomics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bionomics this week, compared to 0 articles on an average week.
  • Search Interest

    7 people have searched for BNOX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Bionomics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bionomics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.69% of the stock of Bionomics is held by insiders.

  • Percentage Held by Institutions

    Only 15.90% of the stock of Bionomics is held by institutions.

  • Read more about Bionomics' insider trading history.
Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

BNOX Stock News Headlines

Bionomics files $100M mixed securities shelf
Bionomics (NASDAQ:BNOX) Earns Outperform Rating from William Blair
Breaking News: Tesla headed to $500…
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
Bionomics receives A$1M milestone payment from Carina Biotech for BNC101
Bionomics to Present at the ThinkEquity Conference
See More Headlines

BNOX Stock Analysis - Frequently Asked Questions

Bionomics' stock was trading at $1.48 at the beginning of 2024. Since then, BNOX stock has decreased by 80.1% and is now trading at $0.2946.
View the best growth stocks for 2024 here
.

Bionomics (BNOX) raised $20 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share.

Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include Meta Platforms (META), Palantir Technologies (PLTR), PayPal (PYPL), Intel (INTC), ChargePoint (CHPT), CRISPR Therapeutics (CRSP) and NVIDIA (NVDA).

Company Calendar

Today
11/24/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BNOX
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+2,615.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$0.99 per share

Miscellaneous

Free Float
17,200,000
Market Cap
$5.10 million
Optionable
Not Optionable
Beta
-0.07
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:BNOX) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners